Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Docking protein-1 promotes inflammatory macrophage signaling in gastric cancer.

Li T, Li B, Sara A, Ay C, Leung WY, Zhang Y, Dong Y, Liang Q, Zhang X, Weidner P, Gutting T, Behrens HM, Röcken C, Sung JJ, Ebert MP, Yu J, Burgermeister E.

Oncoimmunology. 2019 Aug 21;8(11):e1649961. doi: 10.1080/2162402X.2019.1649961. eCollection 2019.

PMID:
31646096
2.

Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A.

Burgermeister E, Battaglin F, Eladly F, Wu W, Herweck F, Schulte N, Betge J, Härtel N, Kather JN, Weis CA, Gaiser T, Marx A, Weiss C, Hofheinz R, Miller IS, Loupakis F, Lenz HJ, Byrne AT, Ebert MP.

EBioMedicine. 2019 Jul;45:139-154. doi: 10.1016/j.ebiom.2019.07.004. Epub 2019 Jul 9.

3.

MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer.

Zhan T, Ambrosi G, Wandmacher AM, Rauscher B, Betge J, Rindtorff N, Häussler RS, Hinsenkamp I, Bamberg L, Hessling B, Müller-Decker K, Erdmann G, Burgermeister E, Ebert MP, Boutros M.

Nat Commun. 2019 May 16;10(1):2197. doi: 10.1038/s41467-019-09898-0.

4.

A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA).

Meindl-Beinker NM, Betge J, Gutting T, Burgermeister E, Belle S, Zhan T, Schulte N, Maenz M, Ebert MP, Haertel N.

BMC Cancer. 2019 Mar 14;19(1):231. doi: 10.1186/s12885-019-5446-2.

5.

Spatial Distribution of Endogenous Tissue Protease Activity in Gastric Carcinoma Mapped by MALDI Mass Spectrometry Imaging.

Erich K, Reinle K, Müller T, Munteanu B, Sammour DA, Hinsenkamp I, Gutting T, Burgermeister E, Findeisen P, Ebert MP, Krijgsveld J, Hopf C.

Mol Cell Proteomics. 2019 Jan;18(1):151-161. doi: 10.1074/mcp.RA118.000980. Epub 2018 Oct 7.

PMID:
30293968
6.

Impact of direct acting antiviral (DAA) treatment on glucose metabolism and reduction of pre-diabetes in patients with chronic hepatitis C.

Weidner P, Boettche D, Zimmerer T, Burgermeister E, Teufel A, Ebert MPA, Antoni C.

J Gastrointestin Liver Dis. 2018 Sep;27(3):281-289. doi: 10.15403/jgld.2014.1121.273.daa.

7.

A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/- nab-paclitaxel in elderly pancreatic cancer patients (GrantPax).

Betge J, Chi-Kern J, Schulte N, Belle S, Gutting T, Burgermeister E, Jesenofsky R, Maenz M, Wedding U, Ebert MP, Haertel N.

BMC Cancer. 2018 Jul 18;18(1):747. doi: 10.1186/s12885-018-4665-2.

8.

PPARγ-activation increases intestinal M1 macrophages and mitigates formation of serrated adenomas in mutant KRAS mice.

Gutting T, Weber CA, Weidner P, Herweck F, Henn S, Friedrich T, Yin S, Kzhyshkowska J, Gaiser T, Janssen KP, Reindl W, Ebert MPA, Burgermeister E.

Oncoimmunology. 2018 Feb 1;7(5):e1423168. doi: 10.1080/2162402X.2017.1423168. eCollection 2018.

9.

Checkpoints and beyond - Immunotherapy in colorectal cancer.

Gutting T, Burgermeister E, Härtel N, Ebert MP.

Semin Cancer Biol. 2019 Apr;55:78-89. doi: 10.1016/j.semcancer.2018.04.003. Epub 2018 Apr 30. Review.

PMID:
29716829
10.

Epigenetic silencing of tumor suppressor candidate 3 confers adverse prognosis in early colorectal cancer.

Burgermeister E, Höde P, Betge J, Gutting T, Merkel A, Wu W, Tänzer M, Mossner M, Nowak D, Magdeburg J, Rückert F, Sticht C, Breitkopf-Heinlein K, Schulte N, Härtel N, Belle S, Post S, Gaiser T, Heppner BI, Behrens HM, Röcken C, Ebert MPA.

Oncotarget. 2017 Sep 15;8(49):84714-84728. doi: 10.18632/oncotarget.20950. eCollection 2017 Oct 17.

11.

Inhibition of Rho-Associated Kinase 1/2 Attenuates Tumor Growth in Murine Gastric Cancer.

Hinsenkamp I, Schulz S, Roscher M, Suhr AM, Meyer B, Munteanu B, Fuchser J, Schoenberg SO, Ebert MP, Wängler B, Hopf C, Burgermeister E.

Neoplasia. 2016 Aug;18(8):500-11. doi: 10.1016/j.neo.2016.07.002.

12.

Subcellular compartmentalization of docking protein-1 contributes to progression in colorectal cancer.

Friedrich T, Söhn M, Gutting T, Janssen KP, Behrens HM, Röcken C, Ebert MPA, Burgermeister E.

EBioMedicine. 2016 Jun;8:159-172. doi: 10.1016/j.ebiom.2016.05.003. Epub 2016 May 5.

13.

Myotubularin-related protein 7 inhibits insulin signaling in colorectal cancer.

Weidner P, Söhn M, Gutting T, Friedrich T, Gaiser T, Magdeburg J, Kienle P, Ruh H, Hopf C, Behrens HM, Röcken C, Hanoch T, Seger R, Ebert MP, Burgermeister E.

Oncotarget. 2016 Aug 2;7(31):50490-50506. doi: 10.18632/oncotarget.10466.

14.

Spatial Autocorrelation in Mass Spectrometry Imaging.

Cassese A, Ellis SR, Ogrinc Potočnik N, Burgermeister E, Ebert M, Walch A, van den Maagdenberg AM, McDonnell LA, Heeren RM, Balluff B.

Anal Chem. 2016 Jun 7;88(11):5871-8. doi: 10.1021/acs.analchem.6b00672. Epub 2016 May 24.

PMID:
27180608
15.

Label-free in situ monitoring of histone deacetylase drug target engagement by matrix-assisted laser desorption ionization-mass spectrometry biotyping and imaging.

Munteanu B, Meyer B, von Reitzenstein C, Burgermeister E, Bog S, Pahl A, Ebert MP, Hopf C.

Anal Chem. 2014 May 20;86(10):4642-7. doi: 10.1021/ac500038j. Epub 2014 Mar 11.

PMID:
24559101
16.

Deficiency of caveolin-1 in Apc(min/+) mice promotes colorectal tumorigenesis.

Friedrich T, Richter B, Gaiser T, Weiss C, Janssen KP, Einwächter H, Schmid RM, Ebert MP, Burgermeister E.

Carcinogenesis. 2013 Sep;34(9):2109-18. doi: 10.1093/carcin/bgt142. Epub 2013 May 2.

PMID:
23640045
17.

Caveolin-1 protects B6129 mice against Helicobacter pylori gastritis.

Hitkova I, Yuan G, Anderl F, Gerhard M, Kirchner T, Reu S, Röcken C, Schäfer C, Schmid RM, Vogelmann R, Ebert MP, Burgermeister E.

PLoS Pathog. 2013;9(4):e1003251. doi: 10.1371/journal.ppat.1003251. Epub 2013 Apr 11.

18.

Bile acids down-regulate caveolin-1 in esophageal epithelial cells through sterol responsive element-binding protein.

Prade E, Tobiasch M, Hitkova I, Schäffer I, Lian F, Xing X, Tänzer M, Rauser S, Walch A, Feith M, Post S, Röcken C, Schmid RM, Ebert MP, Burgermeister E.

Mol Endocrinol. 2012 May;26(5):819-32. doi: 10.1210/me.2011-1140. Epub 2012 Apr 3.

19.

Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2.

Regel I, Merkl L, Friedrich T, Burgermeister E, Zimmermann W, Einwächter H, Herrmann K, Langer R, Röcken C, Hofheinz R, Schmid R, Ebert MP.

Gastroenterology. 2012 Jul;143(1):99-109.e10. doi: 10.1053/j.gastro.2012.03.035. Epub 2012 Mar 27.

PMID:
22465428
20.

WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin in human gastric cancer cells.

Yuan G, Regel I, Lian F, Friedrich T, Hitkova I, Hofheinz RD, Ströbel P, Langer R, Keller G, Röcken C, Zimmermann W, Schmid RM, Ebert MP, Burgermeister E.

Oncogene. 2013 Jan 17;32(3):375-87. doi: 10.1038/onc.2012.40. Epub 2012 Feb 27.

PMID:
22370641
21.

TFAP2E-DKK4 and chemoresistance in colorectal cancer.

Ebert MP, Tänzer M, Balluff B, Burgermeister E, Kretzschmar AK, Hughes DJ, Tetzner R, Lofton-Day C, Rosenberg R, Reinacher-Schick AC, Schulmann K, Tannapfel A, Hofheinz R, Röcken C, Keller G, Langer R, Specht K, Porschen R, Stöhlmacher-Williams J, Schuster T, Ströbel P, Schmid RM.

N Engl J Med. 2012 Jan 5;366(1):44-53. doi: 10.1056/NEJMoa1009473.

22.

The Ras inhibitors caveolin-1 and docking protein 1 activate peroxisome proliferator-activated receptor γ through spatial relocalization at helix 7 of its ligand-binding domain.

Burgermeister E, Friedrich T, Hitkova I, Regel I, Einwächter H, Zimmermann W, Röcken C, Perren A, Wright MB, Schmid RM, Seger R, Ebert MP.

Mol Cell Biol. 2011 Aug;31(16):3497-510. doi: 10.1128/MCB.01421-10. Epub 2011 Jun 20.

23.

Farnesoid X receptor protects human and murine gastric epithelial cells against inflammation-induced damage.

Lian F, Xing X, Yuan G, Schäfer C, Rauser S, Walch A, Röcken C, Ebeling M, Wright MB, Schmid RM, Ebert MP, Burgermeister E.

Biochem J. 2011 Sep 1;438(2):315-23. doi: 10.1042/BJ20102096.

PMID:
21619550
24.

Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy.

Xing X, Burgermeister E, Geisler F, Einwächter H, Fan L, Hiber M, Rauser S, Walch A, Röcken C, Ebeling M, Wright MB, Schmid RM, Ebert MP.

Hepatology. 2009 Mar;49(3):979-88. doi: 10.1002/hep.22712.

PMID:
19072826
25.

PPARgamma and MEK Interactions in Cancer.

Burgermeister E, Seger R.

PPAR Res. 2008;2008:309469. doi: 10.1155/2008/309469.

26.
27.

Caveats of caveolin-1 in cancer progression.

Burgermeister E, Liscovitch M, Röcken C, Schmid RM, Ebert MP.

Cancer Lett. 2008 Sep 18;268(2):187-201. doi: 10.1016/j.canlet.2008.03.055. Epub 2008 May 14. Review.

PMID:
18482795
28.

Differential expression and function of caveolin-1 in human gastric cancer progression.

Burgermeister E, Xing X, Röcken C, Juhasz M, Chen J, Hiber M, Mair K, Shatz M, Liscovitch M, Schmid RM, Ebert MP.

Cancer Res. 2007 Sep 15;67(18):8519-26.

29.

MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma.

Burgermeister E, Seger R.

Cell Cycle. 2007 Jul 1;6(13):1539-48. Epub 2007 May 18. Review.

PMID:
17611413
30.

Perspectives of clinical proteomics in gastrointestinal cancer.

Ebert M, Xing X, Burgermeister E, Schmid R, Röcken C.

Expert Rev Anticancer Ther. 2007 Apr;7(4):465-9. Review.

PMID:
17428167
31.

Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma.

Burgermeister E, Chuderland D, Hanoch T, Meyer M, Liscovitch M, Seger R.

Mol Cell Biol. 2007 Feb;27(3):803-17. Epub 2006 Nov 13.

32.

A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro.

Burgermeister E, Schnoebelen A, Flament A, Benz J, Stihle M, Gsell B, Rufer A, Ruf A, Kuhn B, Märki HP, Mizrahi J, Sebokova E, Niesor E, Meyer M.

Mol Endocrinol. 2006 Apr;20(4):809-30. Epub 2005 Dec 22.

PMID:
16373399
33.

Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells.

Burgermeister E, Tencer L, Liscovitch M.

Oncogene. 2003 Jun 19;22(25):3888-900.

PMID:
12813462
34.

Activation of cytosolic phospholipase A2 in human T-lymphocytes involves inhibitor-kappaB and mitogen-activated protein kinases.

Burgermeister E, Endl J, Scheuer WV.

Eur J Pharmacol. 2003 Apr 11;466(1-2):169-80.

PMID:
12679154
35.

Comparative analysis of docking motifs in MAP-kinases and nuclear receptors.

Burgermeister E, Lanzendoerfer M, Scheuer W.

J Biomol Struct Dyn. 2003 Apr;20(5):623-34.

PMID:
12643765
36.

Inhibition of cytosolic phospholipase A(2) attenuates activation of mitogen-activated protein kinases in human monocytic cells.

Burgermeister E, Pessara U, Tibes U, Küster A, Heinrich PC, Scheuer WV.

Eur J Pharmacol. 2000 Feb 4;388(3):195-208.

PMID:
10675727
37.

Activation of nuclear factor-kappaB by lipopolysaccharide in mononuclear leukocytes is prevented by inhibitors of cytosolic phospholipase A2.

Burgermeister E, Tibes U, Stockinger H, Scheuer WV.

Eur J Pharmacol. 1999 Mar 26;369(3):373-86.

PMID:
10225377

Supplemental Content

Loading ...
Support Center